Cost-effectiveness of early detection of breast cancer in Catalonia (Spain)

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Carles, Misericordia ^a   Vilaprinyo, Ester ^b   Cots, Francesc ^b   Gregori, Aleix ^a   Pla, Roger ^c   Román, Rubén ^b   Sala, Maria ^b   Macià, Francesc ^b   Castells, Xavier ^b   Rue, Montserrat ^d  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

^d UNIVERSITY OF LLEIDA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; LIFE EXTENSION; MAMMOGRAPHY; OUTCOME ASSESSMENT; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SPAIN; STOCHASTIC MODEL; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; LIFE EXPECTANCY; MIDDLE AGED; MORTALITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIFE EXPECTANCY; MAMMOGRAPHY; MIDDLE AGED; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; SPAIN;

EID: 79956214824     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-192     Document Type: Article

References (48)

1. Izquierdo A, Gispert R, Saladie F, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985-2019: Breast cancer. Med Clin (Barc) 2008, 131(Suppl 1):50-52.
2. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009, 27(13):2111-2113. 10.1200/JCO.2008.21.0534, 19332715.
3. Wolstenholme JL, Smith SJ, Whynes DK. The costs of treating breast cancer in the United Kingdom: implications for screening. Int J Technol Assess Health Care 1998, 14(2):277-289. 10.1017/S0266462300012253, 9611903.
4. Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S. Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 2003, 14(7):1057-1063. 10.1093/annonc/mdg280, 12853347.
5. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. What is an efficient health technology in Spain?. Gac Sanit 2002, 16(4):334-343.
6. Plans P, Casademont L, Salleras L. Cost-effectiveness of breast cancer screening in Spain. Int J Technol Assess Health Care 1996, 12(1):146-150. 10.1017/S0266462300009478, 8690555.
7. Beemsterboer PMM, Warmerdam PG, Boer R, Borras JM, Moreno V, Viladiu P, de Konning HJ. Screening for breast cancer in Catalonia. Which policy is to be preferred?. Eur J Public Health 1998, 8(3):241-246.
8. Garuz R, Forcen T, Cabases J, Antonanzas F, Trinxet C, Rovira J, Anton F. Economic evaluation of a mammography-based breast cancer screening programme in Spain. Eur J Public Health 1997, 7(1):68-76.
9. van den Akker-van Marle ME, Reep-van den Bergh CM, Boer R, Del Moral A, Ascunce N, de Koning HJ. Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. Int J Cancer 1997, 73(4):464-469. 10.1002/(SICI)1097-0215(19971114)73:4<464::AID-IJC2>3.0.CO;2-Y, 9389557.
10. Rue M, Vilaprinyo E, Lee S, Martinez-Alonso M, Carles M, Marcos-Gragera R, Pla R, Espinas JA. Effectiveness of early detection on breast cancer mortality reduction in Catalonia (Spain). BMC Cancer 2009, 9(1):326. 10.1186/1471-2407-9-326, 2758899, 19754959.
11. Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006, (36):79-86.
12. Lee SJ, Zelen M. Mortality modeling of early detection programs. Biometrics 2008, 64(2):386-395. 10.1111/j.1541-0420.2007.00893.x, 17725809.
13. Wolfram Research Inc Mathematica, Version 7.0. Illinois 2008, Wolfram Research Inc.
14. R Development Core Team R: A Language and Environment for Statistical Computing, Version 2.11.1. Viena 2011, R Development Core Team.
15. Stata Corporation Stata/SE, Version 11.0. Texas 2009, Stata Corporation.
16. Zelen M, Lee SJ. Models and the early detection of disease: methodological considerations. Cancer Treat Res 2002, 113:1-18.
17. Lee SJ, Zelen M. Modelling the early detection of breast cancer. Ann Oncol 2003, 14(8):1199-1202. 10.1093/annonc/mdg323, 12881377.
18. Lee S, Huang H, Zelen M. Early detection of disease and scheduling of screening examinations. Stat Methods Med Res 2004, 13(6):443-56. 10.1191/0962280204sm377ra, 15587433.
19. Lee SJ, Zelen M. Scheduling periodic examinations for the early detection of disease: Applications to breast cancer. Journal of the American Statistical Association 1998, 93(444):1271-1281.
20. Vilaprinyo E, Gispert R, Martinez-Alonso M, Carles M, Pla R, Espinas JA, Rue M. Competing risks to breast cancer mortality in Catalonia. BMC Cancer 2008, 8(1):331. 10.1186/1471-2407-8-331, 2636833, 19014473.
21. Rue M, Carles M, Vilaprinyo E, Martinez-Alonso M, Espinas JA, Pla R, Brugulat P. Dissemination of periodic mammography and patterns of use, by birth cohort, in Catalonia (Spain). BMC Cancer 2008, 8:336. 10.1186/1471-2407-8-336, 2613154, 19014679.
22. Vilaprinyo E, Rue M, Marcos-Gragera R, Martinez-Alonso M. Estimation of age- and stage-specific Catalan breast cancer survival functions using US and Catalan survival data. BMC Cancer 2009, 9:98. 10.1186/1471-2407-9-98, 2679763, 19331670.
23. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006, 98(11):774-782. 10.1093/jnci/djj210, 16757702.
24. Lopez Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J. A proposed guideline for economic evaluation of health technologies. Gac Sanit 2010, 24(2):154-170. 10.1016/j.gaceta.2009.07.011, 19959258.
25. Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X, . Cumulative False Positive Risk Group Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol Mar 23, 2011, Cumulative False Positive Risk Group.
26. UK Trial of Early Detection of Breast Cancer Group Specificity of screening in United Kingdom trial of early detection of breast cancer. BMJ 1992, 304(6823):346-349. 1881232, 1540731, UK Trial of Early Detection of Breast Cancer Group.
27. Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst Monogr 2006, 36(36):112-121.
28. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care 1991, 29(1):40-49. 10.1097/00005650-199101000-00004, 1986176.
29. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33(8):828-841. 10.1097/00005650-199508000-00007, 7637404.
30. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995, 87(6):417-426. 10.1093/jnci/87.6.417, 7861461.
31. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000, 36(6):724-735. 10.1016/S0959-8049(99)00340-8, 10762744.
32. de Koning HJ, van Ineveld BM, de Haes JC, van Oortmarssen GJ, Klijn JG, van der Maas PJ. Advanced breast cancer and its prevention by screening. Br J Cancer 1992, 65(6):950-955. 10.1038/bjc.1992.199, 1977784, 1377485.
33. Richards MA, Braysher S, Gregory WM, Rubens RD. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993, 67(4):856-860. 10.1038/bjc.1993.157, 1968338, 8471446.
34. Guest JF, Ruiz FJ, Greener MJ, Trotman IF. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 2006, 15(1):65-73.
35. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health 2000, 3(1):23-30. 10.1046/j.1524-4733.2000.31003.x, 16464178.
36. Cantarero D, Lago-Peñas S. Decomposing the determinants of health care expenditure: the case of Spain. Eur J Health Econ 2010,
37. Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009, 27(3):199-209. 10.2165/00019053-200927030-00003, 19354340.
38. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA 1995, 274(11):881-884. 10.1001/jama.274.11.881, 7674501.
39. Wong IO, Kuntz KM, Cowling BJ, Lam CL, Leung GM. Cost effectiveness of mammography screening for Chinese women. Cancer 2007, 110(4):885-895. 10.1002/cncr.22848, 17607668.
40. Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev 2009, 18(3):718-725. 10.1158/1055-9965.EPI-08-0918, 2716399, 19258473.
41. Lee SY, Jeong SH, Kim YN, Kim J, Kang DR, Kim HC, Nam CM. Cost-effective mammography screening in Korea: High incidence of breast cancer in young women. Cancer Sci 2009, 100(6):1105-1111. 10.1111/j.1349-7006.2009.01147.x, 19320639.
42. De Koning HJ. Breast cancer screening; cost-effective in practice?. Eur J Radiol 2000, 33(1):32-37. 10.1016/S0720-048X(99)00105-9, 10674787.
43. Feuer EJ. Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monogr 2006, (36):2-6.
44. National Institute for Health and Clinical Excellence (NICE) National Institute for Health and Clinical Excellence (NICE)., http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp
45. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol 1996, 49(1):95-103. 10.1016/0895-4356(96)89259-6, 8598518.
46. Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ 2005, 6(4):309-313. 10.1007/s10198-005-0303-4, 16133097.
47. Jonsson B, Staginnus U, Wilking N. The burden and costs of cancer in Spain [La carga y el coste del cancer en España]. ReES 2007, 6(3):141-147.
48. Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M. Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res 2010, 12(4):R58. 10.1186/bcr2620, 2949650, 20682042.